New treatment pathways for giant cell tumor of bone (GCTB) and chordoma make their debut in the updated version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for bone cancer, joining those for osteosarcoma, nonmetastatic Ewing’s sarcoma, and chondrosarcoma. Guidelines for managing these bone cancers are especially important, given the rarity of these neoplasms and most clinicians’ lack of familiarity with them, said J. Sybil Biermann, MD, Professor and Medical Director of the Sarcoma Program at the University of Michigan Comprehensive Cancer Center in Ann Arbor, and Chair of the NCCN Guidelines Panel on Bone Cancer. Although metastatic osteosarcoma was also newly added to the guidelines, it was not included in Dr. Biermann’s presentation, as it generally follows the previous recommendations for osteosarcoma.
Dr. Biermann has disclosed that she has no financial interests, arrangement, commercial interest conflicts, or affiliations with the manufacturers of any products discussed in this article or their competitors.
ErraniCRuggieriPAsenzioMA. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev2010;36:1–7.
BeckerWTDohleJBerndL. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am2008;90:1060–1067.
ThomasDHenshawRSkubitzK. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol2010;11:275–280.
BranstetterDGNelsonSDManivelJC. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res2012;18:4415–4424.
MankinHJMankinCJSimonMA. The hazards of the biopsy, revisted. Members of the Musculoskeletal Tumor Society. J Bone Joint Surge Am1996;78:656–663.